Drugmaker Wockhardt on Friday said research and trials on the antibiotic Zaynich are progressing satisfactorily, and it is aiming for an early FY26 launch. Zaynich has a market potential of USD 25 billion, the city-based company's founder chairman Habil Khorakiwala told reporters here.